Skip to main content
SpringerLink
Log in

Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Purpose: Inherited variations in drug metabolizing enzymes may influence drug efficacy. This phase II study assesses the impact of second-line weekly irinotecan (CPT-11)/docetaxel in non-small cell lung cancer (NSCLC) patients, and gauges the uridine diphosphate glucuronosyl transferase (UGT1A1) polymorphism influence in toxicity and antitumor activity. Experimental Design: Fifty-one patients with NSCLC treated with at least one prior chemotherapy regimen were enrolled. Patients received irinotecan 70 mg/m2 followed by docetaxel 25 mg/m2. Both drugs were given on days 1, 8, and 15 every 28 days. UGT1A1 polymorphism were analyzed in blood samples of 47 patients. The UGT1A1 polymorphism are classified according to the number of TA repeats in the promoter region of this gene. Results: Three patients (6%) achieved a partial response and nineteen patients (37%) had stable disease. Median survival was 8 months (95% CI: 4.8–11.2) and 1-year survival 30%. Grade 3–4 hematologic toxicity was low (less than 10% of patients); 15% of patients had grade 3 asthenia and 25% of patients had grade 3/4 diarrhea. The frequency of UGT1A1 genotypes was as follows: 6/6 49%, 6/7 36%, and 7/7 15%. No differences in toxicity were observed according to UGT1A1 polymorphism. A nonsignificant improvement in time to progression (4 vs. 3 months) and median survival (11 vs. 8 months) was detected in patients with the variant alleles (6/7 and 7/7). Conclusions: This weekly irinotecan/docetaxel regimen has shown an acceptable toxicity profile while encouraging median and 1-year survival in heavily pretreated NSCLC patients. The tendency to better prognosis in patients carrying the variant genotypes 6/7 and 7/7 of UGT1A1 gene requires further validation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bunn PA, Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 5: 1087–1100, 1998

    Google Scholar 

  2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, for the Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92–98, 2002

    Google Scholar 

  3. Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19: 3210–3218, 2001

    Google Scholar 

  4. Huisman C, Smit EF, Giaccone G, Postmus PE: Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 18: 3722–3730, 2000

    Google Scholar 

  5. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkess R, Coughlin S, Kim Y, Berile J: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095–2103, 2000

    Google Scholar 

  6. Fossella FV DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miler V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L, and the TAX 320 Non-Small-Cell Lung Cancer Study Group: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum containing chemotherapy regimens. J Clin Oncol 18: 2354–2362, 2000

    Google Scholar 

  7. Koh Y, Nishio K: Mechanisms of action of cancer chemotherapeutic agents: topoisomerase inhibitors. In: Alison MR (ed) The Cancer Handbook. Nature Publishing Group, London, 2002 pp 1313–1322

    Google Scholar 

  8. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucoronosyltransferase isoform 1A1 in the glucoronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101: 847–854, 1998

    Google Scholar 

  9. Iyer L, Hall D, Das S, Mortell MA, Ramírez J, Kim S, Di Rienzo A, Ratain MJ. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65: 576–582, 1999

    Google Scholar 

  10. Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. The Pharmacogenomics J 2: 43–47, 2002

    Google Scholar 

  11. Tarón M, Plasencia C, Abad A, Martin C, Guillot M: Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines. Inv New Drugs 18: 139–147, 2000

    Google Scholar 

  12. Satouchi M, Takada Y, Takeda K, Yamamoto N, Negoro S, Nakagawa K, Matsui K, Kawahara M, Fukuoka M, Ariyoshi H: Randomized phase II study of docetaxel (DOC) plus cisplatin (CDDP) versus DOC plus irinotecan in advanced non-small cell lung cancer (NSCLC): a West Japan Thoracic Oncology Group (WJTOG) study. Proc Am Soc Clin Oncol 20: 329a, 2001 (Abstract 1312)

    Google Scholar 

  13. Font A, Sánchez JM, Rosell R, Tarón M, Martínez E, Guillot M, Manzano JL, Margelí M, Barnadas A, Abad A: Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors. Lung Cancer 37: 213–218, 2002

    Google Scholar 

  14. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B, Chasen M, Hong WK, Raber M: Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer. J Clin Oncol 13: 645–651, 1995

    Google Scholar 

  15. Gandara DR, Vokes E, Green M, Bonomi P, Devore R, Comis R, Carbone D, Karp D, Belani C: Activity of docetaxel in platinum-treated non-small-cell lung cancer. Results of a phase II multicenter trial. J Clin Oncol 18: 131–135, 2000

    Google Scholar 

  16. Crino L, Mosconi AM, Scagliotti G, Selvaggi G, Novello S, Rinaldi M, Della Giulia M, Gridelli C, Rossi A, Calandri C, De Marinis F, Noseda M, Tonato M: Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 17: 2081–2085, 1999

    Google Scholar 

  17. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP: Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18: 1212–1219, 2000

    Google Scholar 

  18. Stemmler HJ, Gutschow K, Sommer H, Malekmohammadi M, Kentenich CH, Forstpointner R, Geuenich S, Bischoff J, Hiddemann W, Heinemann V: Weekly docetaxel (taxotere) in patients with metastatic breast cancer. Ann Oncol 12: 1393–1398, 2001

    Google Scholar 

  19. Gervais R, Ducoloné AMD, Breton JL, Braun D, Lebeau B, Vaylet F, Debieuvre D, Quantin X, Tredaniel J, Mouysset F, Mornet M, Lemarié E, Vergnenegre A, Sun XS, Clouet P, Méry-Mignard D, Quoix E: Multicenter, randomised, phase II trial of docetaxel (taxotere) 75 mg/m2 q3w versus 40 mg/m2 weekly in patients with pretreated non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21: 310a, 2002 (Abstract 1238)

    Google Scholar 

  20. Couteau C, Risse ML, Ducreux M, Lefresne-Soulas F, Riva A, Lebecq A, Ruffié P, Rougier P, Lokiec F, Bruno R, Armand JP: Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors. J Clin Oncol 18: 3545–3552, 2000

    Google Scholar 

  21. Adjei AA, Klein CE, Kastrissios H, Goldberg RM, Alberts SR, Pitot HC, Sloan JA, Reid JM, Hanson LJ, Atherton P, Rubin J, Erlichman C: Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. J Clin Oncol 18: 1116–1123, 2000

    Google Scholar 

  22. Sande JR, Verdirame J, Hillman S, Geyer S, Drevyanko T, Tazelaar H, Jett J, Adjei AA: A phase II study of irinotecan and docetaxel in patients with recurrent non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21: 324a, 2002 (Abstract 1295)

    Google Scholar 

  23. Rougier P, Cutsem EV, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C: Randomised trial of irinotecan versus flurouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352: 1407–1412, 1998

    Google Scholar 

  24. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343; 905–914, 2000

    Google Scholar 

  25. Innocenti F, Iyer L, Ratain MJ: Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Disposition 29: 596–600, 2001

    Google Scholar 

  26. Kehrer DFS, Sparreboom A, Verweij J, Bruijin P, Nierop CA, Van de Schraaf J, Ruijgrok EJ, De Jonge MJA: Modulation of irnotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 7: 1136–1141, 2001

    Google Scholar 

  27. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60: 6921–6926, 2000

    Google Scholar 

  28. Mathijssen RHJ, Van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7: 2182–2194, 2001

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hospital Germans Trias i Pujol, Medical Oncology Service, Badalona, Barcelona, Spain

    Albert Font, José Miguel Sánchez, Miquel Tarón, Eva Martinez-Balibrea, José Luis Manzano, Mireia Margelí, Martin Richardet, Agustí Barnadas, Albert Abad & Rafael Rosell

  2. Department of Preventive Medicine, Free University of Madrid, Spain

    José Javier Sánchez

Authors
  1. Albert Font
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. José Miguel Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miquel Tarón
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eva Martinez-Balibrea
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. José Javier Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. José Luis Manzano
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mireia Margelí
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Martin Richardet
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Agustí Barnadas
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Albert Abad
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Rafael Rosell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rafael Rosell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Font, A., Sánchez, J.M., Tarón, M. et al. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest New Drugs 21, 435–443 (2003). https://doi.org/10.1023/A:1026251202137

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026251202137

Search

Navigation